What is HC Wainwright's Estimate for TRVI Q2 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Trevi Therapeutics in a report issued on Wednesday, May 28th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.13) per share for the quarter. HC Wainwright has a "Buy" rating and a $21.00 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.75) EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $1.66 EPS.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04.

TRVI has been the subject of several other reports. D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. B. Riley reissued a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the company from $9.00 to $29.00 in a report on Monday, March 10th. Oppenheimer upped their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Trevi Therapeutics has a consensus rating of "Buy" and a consensus target price of $18.63.

Trevi Therapeutics Price Performance

Shares of TRVI stock traded up $0.14 during trading hours on Friday, hitting $6.50. The stock had a trading volume of 1,449,006 shares, compared to its average volume of 1,219,251. The firm has a market capitalization of $649.30 million, a PE ratio of -14.77 and a beta of 0.62. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The stock's 50 day moving average is $6.24 and its 200 day moving average is $4.86.

Insiders Place Their Bets

In other news, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. This represents a 51.39% decrease in their position. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company's stock valued at $336,000 after acquiring an additional 69,167 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock valued at $713,000 after acquiring an additional 22,145 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Trevi Therapeutics by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock valued at $414,000 after acquiring an additional 29,700 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Trevi Therapeutics by 44.7% during the fourth quarter. American Century Companies Inc. now owns 78,143 shares of the company's stock valued at $322,000 after acquiring an additional 24,153 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Trevi Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 482,815 shares of the company's stock valued at $1,989,000 after acquiring an additional 49,173 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.